Skip to main content
. Author manuscript; available in PMC: 2022 Aug 20.
Published in final edited form as: Cancer Lett. 2020 Nov 21;500:208–219. doi: 10.1016/j.canlet.2020.11.021

Figure 5.

Figure 5.

A. Metabolic-based viability of cells treated with fucoidan or Hf-BDC-Fucoidan (with or without radiation) across a range of doses. The concentration of free fucoidan is matched to the concentration of fucoidan on the nanopartide surface. B. Experimental plan for C-D demonstrating that nMOF concentration was kept constant across all wells (15 μg/mL) while dual-drug loaded nMOF was spiked into wells. In vitro viability for CT26.wt cells treated with a constant concentration of Hf-RDC and three coating conditions (uncoated, dextran coated, and fucoidan coated) with or without 2 gray and a TT concentration of C. 0.3 μM or D. 9.6 μM Asterisks (*) represent statistically significant difference (p<0.05) analyzed by one-ANOVA. E. Clonogenic assay investigating the radiosensitizing potential of various Hf-BDC-Fucoidan loaded partides. F. Radiation Enhancement Ratio values for all treatments in E compared to no treatment at a given RT dose.